Introduction
============

The application of nanoparticles for biomedical use has increased during the past decades, with its incorporation into drug and gene delivery, bioimaging, and diagnosis.[@b1-ijn-10-371] The nanosystems for biomedicine can be categorized into three groups: metallic, lipid, and polymeric nanoparticles.[@b2-ijn-10-371] Among the three nanosystems, greater efforts have been made recently to develop lipid and polymeric nanoparticles in a clinical setting. Nanostructured lipid carriers (NLCs) are new-generation lipid nanoparticles prepared from both solid and liquid lipids. The core matrix of an NLC is basically soft. NLCs possess some advantages for therapy and diagnosis, including improved drug permeability, reduced adverse response, prolonged half-life, and drug/gene targeting.[@b3-ijn-10-371] Poly(lactic-co-glycolic) acid (PLGA) nanoparticles are frequently used polymeric nanocarriers with biodegradability and biocompatibility. PLGA is approved by the US Food and Drug Administration (FDA) for use in parenteral injections, implants, and drug delivery systems.[@b4-ijn-10-371] PLGA nanoparticles hold a hard matrix in the particulate core. They are widely employed for vaccinations, cancer therapy, and theranostics.[@b5-ijn-10-371] Surface coating exhibits an important role in the functionality of nanomedicine. Cationic components are usually incorporated into nanoparticles for the purpose of improving cell uptake, conjugation with genes, open tight junction, and increased drug loading.[@b6-ijn-10-371],[@b7-ijn-10-371] Such nanosystems are useful in the application of gene therapy, tumor targeting, brain delivery, and immunization.[@b8-ijn-10-371]

A concern with nanosystems is the possibility of adverse effects on cells and organisms due to their smaller size and larger specific surface area compared to bulk materials. The cationic surface of nanoparticles further augments the toxicity,[@b9-ijn-10-371] resulting in limited applicability. Nanoparticles also influence the immunological response of cells. Polymorphonuclear neutrophils (PMNs) play an essential role in immunopathogenesis. Neutrophils participate in the communication networks that form the foundations of immunity. As one of the first cell types to arrive at sites of infection, PMNs secrete cytokines and chemokines that are critical in the unfolding of the inflammatory response and in establishing the correct environmental conditions for launch of the adaptive immune response.[@b10-ijn-10-371] PMNs are the most abundant leukocytes in circulation, representing about 65% of the total blood cells. Neutrophils are the first leukocytes to respond to foreign materials by producing proinflammatory mediators. Excessive activation of PMNs would cause tissue injury. Although some studies have evaluated the effect of metallic nanoparticles on neutrophils,[@b11-ijn-10-371],[@b12-ijn-10-371] few studies have examined the neutrophil response to lipid and polymeric nanoparticles. A detailed investigation of the role of cationic surfactants in nanosystems for cytotoxicity and inflammation of human neutrophils was justified in this study, with an objective to elucidate different effects between lipid and polymeric nanoparticles. Another objective was to examine whether different surfactants could affect the extent of neutrophil activation. The two cationic surfactants used in this work were cetyltrimethylammonium bromide (CTAB) and soyaethyl morpholinium ethosulfate (SME). Both are reported to be toxic to cells and organs, such as fibroblasts, the liver, and kidneys.[@b7-ijn-10-371],[@b13-ijn-10-371]

The nanoparticles were characterized for size, the polydispersity index (PDI), and surface charge before testing neutrophil responses. To achieve the purpose of this study, cell viability, lactate dehydrogenase (LDH) release, degranulation, respiratory burst, and Ca^2+^ influx of PMNs in response to nanodispersions were detected. The cellular uptake and neutrophil morphology after incubation of nanoparticles were also determined to explore mechanisms related to immunomodulation and inflammation.

Materials and methods
=====================

Materials
---------

Soybean oil, Pluronic^®^ F68, CTAB, PLGA (50:50, molecular weight 30--60 kDa), and poly(vinyl alcohol) were provided by Sigma-Aldrich Co. (St Louis, MO, USA). Cetyl palmitate was purchased from Acros (Geel, Belgium). SME was supplied by Croda (East Yorkshire, UK). Soybean phosphatidylcholine (SPC) (Phospholipon^®^ 80H) was from American Lecithin (Oxford, CT, USA). Hydroethidine (HE) and Fura-2 AM were purchased from Thermo Fisher Scientific (Waltham, MA, USA). 1,2-Bis(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid (BAPTA-AM) was from Calbiochem (Billerica, MA, USA). Rhodamine 800 was provided by AAT Bioquest (Sunnyvale, CA, USA).

Preparation of NLCs
-------------------

Soybean oil (6% w/w of the final product), cetyl palmitate (6%), and SPC (1%) were blended as the lipid phase, while the aqueous phase was the mixture of water and Pluronic F68 (3.5%). CTAB or SME (2%) was incorporated in the lipid phase when preparing cationic NLCs at room temperature. Both phases were heated at 85°C for 15 minutes separately. The aqueous phase was mixed into the lipid phase and homogenized by a high-shear homogenizer for 20 minutes at 12,000 rpm. The mixture was further treated with a probe-type sonicator for 15 minutes to produce the final product.

Preparation of PLGA nanoparticles
---------------------------------

Polymeric nanoparticles were manufactured based on a solvent extraction/evaporation technique. PLGA (0.3% w/w of the final product) was dissolved in 3 mL acetone as the organic phase. The aqueous phase was made up of poly(vinyl alcohol) (2.4%) and cationic surfactants (2%) in water. The aqueous phase was heated at 85°C for 15 minutes, and then treated by a probe-type sonicator for 5 minutes. After cooling, the organic phase was slowly pipetted into the aqueous phase. The mixture was stirred overnight to evaporate the organic solvent. Purification of nanoparticles was performed by ultracentrifugation (9,000 rpm for 30 minutes). Pellet resuspension was carried out by vortexing.

Size and zeta potential
-----------------------

The mean diameter (z-average) and zeta potential of nanoparticles were detected using a laser-scattering method (Zetasizer Nano ZS90; Malvern Instruments, Malvern, UK). The nanodispersions were diluted 100-fold with water before testing. The measurement was repeated three times per sample for three batches. The particle number of nanosystems was detected using the qNano particle counter (Izon, Christchurch, New Zealand).

Preparation of human neutrophils
--------------------------------

Human PMNs were purified from healthy volunteers (20--30 years old) using a protocol approved by the institutional review board at Chang Gung Memorial Hospital (Kweishan, Taiwan). The volunteers provided written informed consent in order to participate. Neutrophils were isolated with sedimentation prior to centrifugation in a Ficoll-Hypaque gradient and hypotonic lysis of erythrocyte.[@b14-ijn-10-371]

Cell viability
--------------

Survival of PMNs was measured with a water-soluble tetrazolium (WST) cell proliferation reagent (WST-1) (Hoffman-La Roche Ltd., Basel, Switzerland). Cells (1×10[@b6-ijn-10-371] cells/mL) were treated with various concentrations (1/3,000, 1/1,000, and 1/500 dilution of the nanodispersion) of nanoparticles for 15 minutes at 37°C. The treated medium was centrifuged at 200× *g* for 8 minutes. The supernatant was then removed. WST-1 reagent was added and, after 1 hour's incubation at 37°C, the absorbance was measured at 450 nm.

LDH release
-----------

The LDH level was examined using a commercially available method (CytoTox 96^®^ Cytotoxicity Assay; Promega Corporation, Fitchburg, WI, USA). PMNs (6×10[@b5-ijn-10-371] cells/mL) were equilibrated at 37°C for 2 minutes and then treated with nanoparticles at different concentrations for 15 minutes. The cytotoxicity was represented by LDH release in cell-free medium as a percentage of the total LDH released. The total LDH release was detected by lysing cells with 0.1% Triton X-100.

Elastase release
----------------

MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide was employed as the elastase substrate. After supplementation with the substrate (100 μM), neutrophils (6×10[@b5-ijn-10-371] cells/mL) were equilibrated at 37°C for 2 minutes and then treated with nanoparticles for 15 minutes. The absorbance at 405 nm was monitored for 15 minutes to determine the elastase level.

Intracellular superoxide anion (O~2~^•−^) production
----------------------------------------------------

HE can penetrate into cells and exhibit fluorescence at an excitation wavelength of 480 nm after intracellular oxidation by oxygen radicals. PMNs (2.5×10[@b6-ijn-10-371] cells/mL) were loaded with HE (10 μM) at 37°C for 5 minutes. PMNs were incubated with nanoparticles for 15 minutes at 37°C. After treatment, Hank's balanced salt solution (HBSS) at 4°C was used to stop the reaction, and the fluorescence was monitored by flow cytometry. There were 10,000 cells analyzed on the flow cytometer per sample.

Intracellular Ca^2+^
--------------------

PMNs (3×10[@b6-ijn-10-371] cells/mL) were loaded with Fura-2 AM (2 μM) at 37°C for 40 minutes. After being washed, neutrophils were resuspended in HBSS. Nanoparticles were added into the medium with neutrophils for 15 minutes at 37°C. The change in fluorescence was examined by a spectrofluorometer with continuous stirring. The excitation and emission wavelengths were set at 340/380 nm and 505 nm, respectively. The detailed procedure was described in a previous report.[@b15-ijn-10-371]

Inhibition of Ca^2+^ and inflammatory mediators by BAPTA-AM
-----------------------------------------------------------

In another set of experiments, including determinations of LDH, elastase, O~2~^•−^, and Ca^2+^, BAPTA-AM was joined into neutrophil medium for suppressing Ca^2+^ homeostasis. BAPTA-AM (20 μM) was added into neutrophil suspensions in Ca^2+^-free solution before nanoparticle treatment. The other procedures were in accordance with the methods described in the earlier sections.

Cellular uptake examined by confocal laser scanning microscopy
--------------------------------------------------------------

PMNs (1.8×10[@b7-ijn-10-371] cells/mL) were equilibrated at 37°C for 2 minutes. Subsequently, rhodamine 800-loaded nanoparticles were added into neutrophil medium at 37°C for 5 minutes. The concentration of rhodamine 800 in nanodispersion was 0.1 mg/mL. HBSS was used to terminate the reaction at 4°C. The fluorescence inside the cells was imaged by confocal laser scanning microscopy (CLSM) as a measure of nanoparticle uptake into the cells.

Cell morphology examined by scanning electron microscopy
--------------------------------------------------------

PMNs (1.8×10[@b7-ijn-10-371] cells/mL) were incubated with nanoparticles for 5 minutes. The suspension was centrifuged at 200× *g* at 4°C for 8 minutes. Glutaraldehyde (0.5%) was added to the neutrophils after supernatant removal. A cacodylate buffer with glutaraldehyde (3%) and paraformaldehyde (2%) was added to fix PMNs overnight, then postfixed in cacodylate buffer containing osmium tetraoxide. The cells were dehydrated by ethanol, dried, mounted on stubs, and sputter-coated with gold palladium alloy. The morphology of PMNs was imaged under scanning electron microscopy (SEM).

Statistical analysis
--------------------

Experimental results were expressed as the mean ± standard error of the mean, and comparisons were made based on unpaired Student's *t*-test or analysis of variance (ANOVA). A probability of \<0.001, \<0.01, or \<0.05 was considered significant.

Results
=======

Size and zeta potential
-----------------------

[Table 1](#t1-ijn-10-371){ref-type="table"} demonstrates physicochemical characterization of all nanoparticles tested. The lipid nanoparticles without cationic components (blank NLCs \[N-b\]) showed an average diameter of 255 nm. The size was greatly reduced, to 170 nm (*P*\<0.05), by the incorporation of CTAB (CTAB-coated NLCs \[N-c\]). On the other hand, SME incorporation did not alter the mean diameter of NLCs (SME-coated NLCs \[N-s\]). With respect to polymeric nanoparticles, the average size of the formulation without cationic surfactant (blank PLGA nanoparticles \[P-b\]) was centered on 102 nm. The addition of CTAB (CTAB-coated PLGA nanoparticles \[P-c\]) and SME (SME-coated PLGA nanoparticles \[P-s\]) significantly increased (*P*\<0.05) particulate size, to 246 and 220 nm, respectively. All formulations revealed a PDI of \<0.2 except N-b (PDI =0.33). The nanodispersions with a PDI value of \<0.2 achieved a relatively uniform size. The zeta potential of N-b was negative (−43 mV). CTAB and SME rendered NLCs positively charged (52 mV). The surface charge of unmodified PLGA nanoparticles (P-b) was slightly anionic (−6 mV). Both cationic surfactants provided positive charges to polymeric nanoparticles, with P-s showing a higher charge (39 mV) than CTAB-coated formulations (29 mV). These nanosystems displaying a variety of core materials and surface coatings were then subjected to PMNs for evaluation.

Cell viability
--------------

[Figure 1](#f1-ijn-10-371){ref-type="fig"} summarizes the survival rate of PMNs after incubation of nanoparticles. As shown in [Figure 1A](#f1-ijn-10-371){ref-type="fig"}, NLCs without cationic compounds (N-b) slightly but significantly decreased neutrophil viability at higher concentrations (1/1,000 and 1/500). The P-b did not modify the viability of PMNs. N-c completely inhibited cell viability at all concentrations tested ([Figure 1B](#f1-ijn-10-371){ref-type="fig"}). The cell viability was significantly increased in the group of N-s as compared to the CTAB group ([Figure 1C](#f1-ijn-10-371){ref-type="fig"}). There was a relationship between N-s concentration and reduction in cell survival rate. Cell survival profiles of P-c and P-s were similar to those of lipid nanoparticles ([Figure 1B and C](#f1-ijn-10-371){ref-type="fig"}). In order to examine the contribution of cationic surfactants to cytotoxicity of neutrophils, the cells were exposed to the solutions of corresponding surfactants in the same concentrations as those corresponding to nanosystems ([Figure 1D](#f1-ijn-10-371){ref-type="fig"}). The results showed a complete inhibition of cell viability by CTAB. A lesser inhibition was observed for SME, especially at the lower concentration (1/3,000).

LDH release
-----------

LDH leakage from PMNs reflects cell membrane disruption. [Figure 2](#f2-ijn-10-371){ref-type="fig"} shows LDH release in neutrophils treated with nanoparticles. Lipid and polymeric nanoparticles without cationic surfactants produced no effect on LDH ([Figure 2A](#f2-ijn-10-371){ref-type="fig"}). Positively charged nanoparticles were cytotoxic within the concentrations tested, with CTAB showing greater LDH release than SME ([Figure 2B and C](#f2-ijn-10-371){ref-type="fig"}). As the effect of cationic surfactants was examined, CTAB also increased LDH leakage to a greater extent than SME ([Figure 2D](#f2-ijn-10-371){ref-type="fig"}). At the concentration of 1/3,000, PLGA nanoparticles were less toxic than NLCs according to the LDH level. Polymeric nanoparticles (P-c and P-s) stimulated LDH release in a concentration-dependent manner. It is worth noting that SME at a concentration of 1/3,000 had significantly enhanced LDH in free form, but not in the nanoparticulate form.

Elastase release
----------------

Neutrophil inflammation is a type of immune response in which the body reacts to foreign irritation. One indication is degranulation, which can be measured by elastase release. We evaluated elastase release from PMNs incubated with lipid and polymeric nanoparticles as depicted in [Figure 3](#f3-ijn-10-371){ref-type="fig"}. The nanoparticle concentration selected was 1/3,000. N-c and N-s but not N-b stimulated elastase release by PMNs (*P*\<0.05) ([Figure 3A](#f3-ijn-10-371){ref-type="fig"}). A threefold increase of elastase was detected for cationic NLCs as compared to the control group. Incubation of PMNs with P-c also induced a significant threefold increase (*P*\<0.05) in elastase ([Figure 3B](#f3-ijn-10-371){ref-type="fig"}). Nevertheless, this increase was not observed by P-s. As illustrated in [Figure 3C](#f3-ijn-10-371){ref-type="fig"}, treating CTAB in the free form causes an exponential elevation in elastase release. An elevenfold increase in elastase was detected for free CTAB. This indicates that CTAB loading into nanoparticles could shield its influence on PMNs. Free SME did not cause neutrophil degranulation.

O~2~^•−^ production
-------------------

Another relevant aspect of neutrophil activation is the oxygen-dependent pathway that refers to respiratory burst. Whether this mechanism was involved in cationic nanoparticle-induced activation was explored by examining O~2~^•−^ generation as shown in [Figure 4](#f4-ijn-10-371){ref-type="fig"}. The profiles of O~2~^•−^ production induced by cationic surfactants in nanoparticulate and free forms were similar to those of elastase. NLCs containing CTAB and SME significantly increased O~2~^•−^, by 30- and fourfold, respectively ([Figure 4A](#f4-ijn-10-371){ref-type="fig"}). In the group of polymeric nanoparticles, only CTAB-coated formulations induced an oxygen-dependent mechanism ([Figure 4B](#f4-ijn-10-371){ref-type="fig"}). SME-coated polymeric nanosystems failed to alter basal O~2~^•−^. Both free CTAB and SME increased O~2~^•−^ in PMNs, as shown in [Figure 4C](#f4-ijn-10-371){ref-type="fig"}. Again, a greater response was revealed with CTAB than with SME.

Intracellular Ca^2+^
--------------------

The time course of Ca^2+^ in PMNs after incubation with nanoparticles and cationic surfactants is shown in [Figure 5A](#f5-ijn-10-371){ref-type="fig"}. [Figure 5B](#f5-ijn-10-371){ref-type="fig"} demonstrates the quantification of intracellular Ca^2+^. There was a correlation between Ca^2+^ and O~2~^•−^. Blank and SME-containing nanoparticles exhibited a comparable Ca^2+^ curve compared to the control group ([Figure 5Aa, Ab, Ba, and Bb](#f5-ijn-10-371){ref-type="fig"}). A great increase of Ca^2+^ was observed for CTAB-containing nanoparticles. NLCs with CTAB (ie, N-c) displayed a higher Ca^2+^ concentration in comparison with PLGA nanoparticles. Free CTAB but not SME evoked an immediate increase of Ca^2+^, as shown in [Figure 5Ac and Bc](#f5-ijn-10-371){ref-type="fig"}.

Inhibition of Ca^2+^ and inflammatory mediators by BAPTA-AM
-----------------------------------------------------------

Ca^2+^ influx is a main mechanism of neutrophil activation by inflammatory mediators. BAPTA-AM is a Ca^2+^ influx inhibitor that is used to reduce neutrophil-induced damage during the inflammatory process. PMNs were co-treated with BAPTA-AM to elucidate the role of Ca^2+^ on toxicity induced by nanoparticles. As demonstrated in [Figure 5Ba](#f5-ijn-10-371){ref-type="fig"}, BAPTA-AM partially attenuates the increase in intracellular Ca^2+^ from N-c. The same phenomenon was observed for free CTAB in aqueous solution ([Figure 5Ac and Bc](#f5-ijn-10-371){ref-type="fig"}). On the other hand, Ca^2+^ concentration in PMNs treated with P-c decreased to the baseline level with the addition of BAPTA-AM ([Figure 5Ab and Bb](#f5-ijn-10-371){ref-type="fig"}). The effect of Ca^2+^ on the increase of LDH, elastase, and O~2~^•−^ levels was studied by BAPTA-AM chelating. Some formulations were excluded in this experiment due to the lack of elevation of these mediators in the absence of BAPTA-AM (N-s and P-s for LDH release; P-c, P-s, and free SME for elastase release). [Figure 6A](#f6-ijn-10-371){ref-type="fig"} shows that there was no inhibition in LDH production after exposure to BAPTA-AM. The chelator depleted elastase in cells treated with NLCs containing CTAB or SME ([Figure 6B](#f6-ijn-10-371){ref-type="fig"}). BAPTA-AM also inhibited elastase of the free CTAB group. However, this inhibition did not reach the level of the control group. O~2~^•−^ was suppressed when the cells were treated with BAPTA-AM ([Figure 6C](#f6-ijn-10-371){ref-type="fig"}). This indicates the requirements of intracellular Ca^2+^ for O~2~^•−^ generation in our study.

Cellular uptake examined by CLSM
--------------------------------

PMNs may be responsive to ingesting nanoparticles, and then undergo immunomodulation and inflammatory activation. The effect of cell internalization for nanoparticle-induced neutrophil response was studied by CLSM. As observed in [Figure 7](#f7-ijn-10-371){ref-type="fig"}, the morphology of PMNs treated with free rhodamine 800 was similar to that of the untreated control. A greater degree of fluorescence was noted in the cells exposed to free rhodamine, indicating a cellular inclusion into the cytoplasm. Unlike free dye, NLCs and PLGA nanoparticles containing CTAB were poorly internalized by PMNs. The PMNs treated with N-c showed a disrupted morphology with aggregation. The size of some PMNs treated by CTAB polymeric nanoparticles was larger than that of the untreated PMNs. This may be due to the influx of extracellular water caused by membrane leakage.

Cell morphology examined by SEM
-------------------------------

The appearance of PMNs was further examined by SEM. As shown in [Figure 8](#f8-ijn-10-371){ref-type="fig"}, the control group displays a spherical morphology. The membranes of PMNs treated by N-c were deformed and damaged. The surface morphology was more complex than that of the control. The level of damage seemed to be less for PMNs treated with PLGA nanoparticles than for NLCs. Some pores were found in the cell membrane, possibly indicating the formation of micropores or leaks by PLGA nanoparticles.

Discussion
==========

The loading of cationic surfactants in nanosystems exhibited different effects on particulate size. The diameter of NLCs was not changed by SME incorporation, but it was significantly decreased by the addition of CTAB. This may indicate that CTAB had an emulsifying effect on lipid nanoparticles, contributing to size reduction. SME did not exert this effect on lipid nanoparticles. Contrary to lipid systems, both cationic surfactants increased the size of polymeric nanopar-ticles by \>2-fold. The emulsifier system with a determined hydrophile--lipophile balance can stabilize nanoparticles with a certain polarity.[@b16-ijn-10-371] CTAB and SME may not fit this criterion, and thus did not show emulsifier activity on PLGA nanoparticles. The occupation of cationic surfactants in the interface led to the enlargement of a particulate dimension.

The typical adult has a blood volume of 4.7--5.0 L. The injection volume for the commonly used intravenous medications is between approximately 1 and 5 mL, which shows a dilution of 1/5,000--1/1,000 to the total blood volume. Our tested concentrations of the nanosystems were physiologically relevant to the medical treatment. Previous studies[@b9-ijn-10-371],[@b17-ijn-10-371] have also demonstrated that cytotoxicity of cationic nanoparticles is a result of cell death. The results of cell viability showed that PLGA nanoparticles in the absence of cationic surfactants (P-b) exhibited no apparent cytotoxicity to PMNs. This is consistent with previous reports that PLGA nanoparticles show a negligible cytotoxicity to cells such as fibroblasts, macrophages, and lymphocytes.[@b18-ijn-10-371],[@b19-ijn-10-371] In the absence of cationic coating, lipid nanoparticles (N-b) at higher concentrations elicited slight cell death. SPC and soybean oil in NLCs may be the inducers of cytotoxicity.[@b20-ijn-10-371],[@b21-ijn-10-371] However, the N-b did not alter the release of other mediators from PMNs. This indicates that the adverse effect of SPC and soybean oil was minimal. CTAB and SME possess amino moieties in their structures ([Figure 9](#f9-ijn-10-371){ref-type="fig"}), which would be ionized in a physiological environment and cause a strong interaction to a negatively charged cell membrane. This adherence can result in cell lysis and death. Cell membrane damage is a characteristic of cytotoxicity mediated by necrosis.[@b22-ijn-10-371] Our results showed a relationship between LDH release and neutrophil death, suggesting that PMNs were disintegrated by cationic nanoparticles as evidenced by compromised membrane integrity.

Elastase is packed in granules that are released upon activation.[@b23-ijn-10-371] CTAB in free form demonstrated greater elastase release than that in nanoparticulate form. This may be due to the immobilization of CTAB by the nanoparticulate surface possibly lessening the exposed probability to PMNs as compared to free CTAB molecules. Neutrophil-derived elastase exerts the ability to degrade the extracellular matrix component, resulting in tissue and organ injury.[@b24-ijn-10-371] Production of O~2~^•−^, a precursor of reactive oxygen species, is involved in the destruction of tissues surrounding activated neutrophils. Huang et al[@b25-ijn-10-371] have mentioned that both O~2~^•−^ generation and LDH can reflect oxidative stress of PMNs. As was the case with degranulation, CTAB elicited a greater oxidative burst than SME. Bhattacharjee et al[@b26-ijn-10-371] also suggest that oxidative stress is a principal mechanism for cellular injury induced by cationic nanoparticles. The subsequent risk of respiratory burst elicited by nanoparticles should be concerned, since neutrophil-derived O~2~^•−^ may promote carcinogenesis by genotoxic stress and genomic instability.[@b10-ijn-10-371] Moreover, O~2~^•−^ and proinflammatory mediators trigger a systemic hypersensitivity reaction and shock/disseminated intravascular coagulation.[@b27-ijn-10-371]

An earlier incident during the activation of PMNs is the elevation of intracellular Ca^2+^.[@b28-ijn-10-371],[@b29-ijn-10-371] The same as O~2~^•−^ production, our results showed that CTAB and NLCs were key components generating intracellular Ca^2+^ in PMNs. BAPTA-AM as a chelator can directly suppress Ca^2+^ influx. It was found that BAPTA-AM inhibited Ca^2+^, elastase, and O~2~^•−^ concentrations raised by cationic nanoparticles. According to the experimental profiles shown in this report, we can speculate possible pathways about cytotoxicity and inflammation elicited by nanosystems. Cationic nanoparticles are conceivably incorporated into lipid rafts in plasma membrane,[@b30-ijn-10-371] which are microdomains in the cell membrane with a high level of glycosphingolipids and protein receptors. Previous studies[@b31-ijn-10-371],[@b32-ijn-10-371] indicate the adhesion of lipid and PLGA nanoparticles onto lipid rafts of the cell surface. Exposure of cationic nanoparticles thus compromised the membrane integrity, which allowed LDH elevation and the subsequent release of cellular contents due to leakage. Either Ca^2+^ or O~2~^•−^ initiate membrane disruption pathways in response to nanoparticles.[@b25-ijn-10-371] The loss of membrane integrity leads to Ca^2+^ influx. O~2~^•−^ is released from cytoplasm membrane and intracellular organs as the membrane is stimulated by nanoparticles.[@b33-ijn-10-371] The relationship between Ca^2+^ and O~2~^•−^ has been investigated for human neutrophils. Ca^2+^ mobilization plays a role in regulating O~2~^•−^ secretion by PMNs after triggering Ca^2+^ influx.[@b34-ijn-10-371] Another possibility is that oxidative stress induces oxidant damage, leading to intracellular Ca^2+^ influx and subsequent cell death.[@b35-ijn-10-371] Ca^2+^ and O~2~^•−^ have been shown to play important roles in governing neutrophil degranulation. Ca^2+^ mobilization is necessary for the activation of the elastase pathway.[@b36-ijn-10-371] Oxidative stress can pump electrons into phagocytic vacuoles, causing a movement of compensating ions that activate elastase.[@b37-ijn-10-371] Cytotoxicity and apoptosis of neutrophils occur via the pathways of degranulation and respiratory burst.[@b38-ijn-10-371] The increase of elastase and O~2~^•−^ by nanoparticles confirmed degranulation- and oxygen-dependent inductions of apoptosis.

Although Ca^2+^ influx may be inferred as a mechanism evoking death of PMNs, our results demonstrated a negligible change of LDH after treatment with BAPTA-AM. This suggests that cationic nanoparticles also developed a Ca^2+^-independent cell death. The level of some mediators was not completely inhibited to the normal range by BAPTA-AM. This is possibly due to insufficient inhibition concentration (20 μM) for chelation of Ca^2+^. Another practicability is the possible plenty increase of intracellular Ca^2+^ by the endoplasmic reticulum and Golgi inside the cells but not just extracellular influx.[@b39-ijn-10-371]

Besides cell membrane interaction and fusion, nanoparticle internalization into PMNs may be another factor in cytotoxicity and inflammatory activation. Nanoparticles can be endocytosed by cells through pinocytosis and clathrin- and caveolin-mediated routes.[@b40-ijn-10-371] Based on CLSM imaging, rhodamine-loaded nanoparticles had a minimal effect to be internalized into PMNs as compared to free dye. It is possible for polymer chains in polymeric nanoparticles to form a steric barrier, thus avoiding the phagocytic process.[@b41-ijn-10-371],[@b42-ijn-10-371] Modification of lipid nanoparticles by Pluronic F68 also reduces cellular uptake by PMNs.[@b43-ijn-10-371] The membrane collapse by cationic nanosystems as observed by CLSM and SEM correlated well with the reduced neutrophil viability. The experimental result showed that neutrophil activation was not necessarily correlated to cellular uptake. Interaction between the cell membrane and nanoparticles was enough to trigger a biological effect.

It is generally accepted that nanoparticles presenting more positive charges can facilitate a biological effect more easily because of their affinity to negatively charged membrane. Lipid nanoparticles exhibited a higher positive charge than polymeric nanoparticles, leading to greater cytotoxicity to PMNs. The zeta potential of CTAB-containing formulations did not surpass that of SME-containing formulations, although CTAB exerted higher activation on PMNs. This indicates that the surface charge was not the sole factor regulating interaction between PMNs and cationic nanoparticles. N-c showed a smaller size and a larger total surface area than N-s; this resulted in a greater toxic effect on PMNs. However, this inference cannot explain the case of polymeric nanoparticles, since the size of CTAB-coated formulations was larger than that of SME-coated ones. Particulate size did not necessarily imply neutrophil activation. Neutrophil response to cationic nanoparticles was dependent upon the particulate types and surfactants selected. The particulate cores of lipid and PLGA nanosystems can be considered to be soft and rigid, respectively. High flexibility of nanoparticles can act as a positive factor for interaction and fusion with the plasma membrane.[@b44-ijn-10-371] This may be the reason why lipid nanoparticles displayed a greater neutrophil response than polymeric nanoparticles. We also determined the number of particles in N-c and PLGA nanoparticles using the qNano particle counter. The particle concentration of N-c and P-c was 1.5×10[@b12-ijn-10-371] and 1.1×10[@b11-ijn-10-371] particles/mL, respectively. The higher concentration of NLCs than PLGA nanoparticles was the possible reason for greater responses being exhibited.

The molecular structure of surfactants at the interface of nanoparticles influences the biophysical interaction with the cell membrane. To summarize the above results pertaining to cytotoxicity and immunomodulation, CTAB in free or nanoparticulate form was more cytotoxic to PMNs than SME. The quaternary ammonium group in the structures of CTAB and SME was the main moiety producing cytotoxicity. Both CTAB and SME possessed an alkyl chain to be entrapped into particulate cores, while the hydrophilic amino group was exposed outside the shells. As shown in [Figure 9](#f9-ijn-10-371){ref-type="fig"}, the N^+^ of CTAB in nanoparticles may directly interact with PMNs due to its location in the margin of the structure. Peetla and Labhasetwar[@b45-ijn-10-371] also reported that CTAB-coated polymeric nanoparticles strongly anchored onto the lipid domains of the endothelial cell membrane. On the other hand, the N^+^ in SME was enclosed in a morpholin six-membrane structure. The SME structure shielded the quaternary ammonium, resulting in difficulty contacting the plasma membrane.

Conclusion
==========

Cationic additives in nanoparticles could trigger cell death and toxic responses. Inflammatory mediators of PMNs including elastase and intracellular Ca^2+^ were increased by cationic nanoparticles. These nanosystems also induced O~2~^•−^ generation. The mechanisms of cytotoxicity or inflammation caused by cationic nanoparticles can be proposed based on experimental data in the present study. The lipid rafts in the plasma membrane are the targets of nanoparticles. The particles interact with the cell membrane, triggering membrane disruption and leakage. Intracellular Ca^2+^ is increased due to this disruption, leading to O~2~^•−^ generation. Both Ca^2+^ and O~2~^•−^ elevation can induce degranulation of PMNs. The cell death occurs because of the production of oxidative stress and excitation of inflammation. The nature of the particulate core and the type of cationic surfactants play key roles in the neutrophil response. Lipid nanoparticles generally revealed a greater response to PMNs than polymeric nanoparticles. Inflammatory activation raised by nanoparticulate coating with CTAB was more significant compared to SME coating due to the structural differences. The size and surface charge did not greatly affect the responses to PMNs. We demonstrated that cationic nanoparticles altered the immune response and homeostasis of PMNs. The mediators evaluated in this work may act as efficient markers for diagnosing nanoparticulate toxicity. The fact that nanoparticles exhibited some properties of immunomodulation and inflammation could be of help for designing clinically acceptable nanosystems.
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**Notes:** (**A**) Blank nanosystems; (**B**) CTAB-loaded nanosystems; (**C**) SME-loaded nanosystems; (**D**) free cationic surfactants. All data are expressed as the mean ± SEM (n=4). \**P*\<0.05; \*\*\**P*\<0.001 compared to the control.\
**Abbreviations:** CTAB, cetyltrimethylammonium bromide; N-b, blank NLCs; N-c, CTAB-coated NLCs; NLCs, nanostructured lipid carriers; N-s, SME-coated NLCs; P-b, blank PLGA nanoparticles; P-c, CTAB-coated PLGA nanoparticles; PLGA, poly(lactic-co-glycolic) acid; P-s, SME-coated PLGA nanoparticles; SEM, standard error of the mean; SME, soyaethyl morpholinium ethosulfate.](ijn-10-371Fig1){#f1-ijn-10-371}

![Effects of nanosystems and free cationic surfactants at different concentrations on LDH release from human neutrophils.\
**Notes:** (**A**) Blank nanosystems; (**B**) CTAB-loaded nanosystems; (**C**) SME-loaded nanosystems; (**D**) free cationic surfactants. All data are expressed as the mean ± SEM. (n=4). \*\**P*\<0.01; \*\*\**P*\<0.001 compared to the control.\
**Abbreviations:** CTAB, cetyltrimethylammonium bromide; LDH, lactate dehydrogenase; N-b, blank NLCs; N-c, CTAB-coated NLCs; NLCs, nanostructured lipid carriers; N-s, SME-coated NLCs; P-b, blank PLGA nanoparticles; P-c, CTAB-coated PLGA nanoparticles; PLGA, poly(lactic-co-glycolic) acid; P-s, SME-coated PLGA nanoparticles; SEM, standard error of the mean; SME, soyaethyl morpholinium ethosulfate.](ijn-10-371Fig2){#f2-ijn-10-371}

![Effects of nanoparticles and cationic surfactants on elastase release from human neutrophils.\
**Notes:** (**A**) Lipid nanoparticles; (**B**) polymeric nanoparticles; (**C**) cationic surfactants. All data are expressed as the mean ± SEM (n=4). \**P*\<0.05; \*\*\**P*\<0.001 compared to the control.\
**Abbreviations:** CTAB, cetyltrimethylammonium bromide; N-b, blank NLCs; N-c, CTAB-coated NLCs; NLCs, nanostructured lipid carriers; N-s, SME-coated NLCs; P-b, blank PLGA nanoparticles; P-c, CTAB-coated PLGA nanoparticles; PLGA, poly(lactic-co-glycolic) acid; P-s, SME-coated PLGA nanoparticles; SEM, standard error of the mean; SME, soyaethyl morpholinium ethosulfate.](ijn-10-371Fig3){#f3-ijn-10-371}

![Effects of nanoparticles and cationic surfactants on O~2~^•−^ production of human neutrophils.\
**Notes:** (**A**) Lipid nanoparticles; (**B**) polymeric nanoparticles; (**C**) cationic surfactants. All data are expressed as the mean ± SEM (n=4). \**P*\<0.05; \*\**P*\<0.01; compared to the control.\
**Abbreviations:** CTAB, cetyltrimethylammonium bromide; HE, hydroethidine; N-b, blank NLCs; N-c, CTAB-coated NLCs; NLCs, nanostructured lipid carriers; N-s, SME-coated NLCs; P-b, blank PLGA nanoparticles; P-c, CTAB-coated PLGA nanoparticles; PLGA, poly(lactic-co-glycolic) acid; P-s, SME-coated PLGA nanoparticles; SEM, standard error of the mean; SME, soyaethyl morpholinium ethosulfate.](ijn-10-371Fig4){#f4-ijn-10-371}

![The effect of nanoparticles and cationic surfactants on Ca^2+^ mobilization in human neutrophils.\
**Notes:** Typical traces and intracellular Ca^2+^ of the effect of (**A**) lipid nanoparticles, (**B**) polymeric nanoparticles, and (**C**) cationic surfactants. Intracellular Ca^2+^ of human neutrophils treated with nanoparticles and cationic surfactants was determined with or without BAPTA-AM (20 μM). Some formulations were excluded in the BAPTA-AM experiment due to the lack of elevation of these mediators in the absence of BAPTA-AM. \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001 compared to the control. ^\#^*P*\<0.05; ^\#\#^*P*\<0.01; compared to the corresponding control.\
**Abbreviations:** BAPTA-AM, 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid; CTAB, cetyltrimethylammonium bromide; N-b, blank NLCs; N-c, CTAB-coated NLCs; NLCs, nanostructured lipid carriers; N-s, SME-coated NLCs; P-b, blank PLGA nanoparticles; P-c, CTAB-coated PLGA nanoparticles; PLGA, poly(lactic-co-glycolic) acid; P-s, SME-coated PLGA nanoparticles; s, seconds; SME, soyaethyl morpholinium ethosulfate.](ijn-10-371Fig5){#f5-ijn-10-371}

![Effects of treatment of human neutrophils with nanoparticles and cationic surfactants with or without BAPTA-AM (20 μM).\
**Notes:** (**A**) LDH release; (**B**) elastase release; (**C**) O~2~^•−^ production. Some formulations were excluded in the BAPTA-AM experiment due to the lack of elevation of these mediators in the absence of BAPTA-AM. \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001 compared to the control. ^\#^*P*\<0.05; compared to the corresponding control.\
**Abbreviations:** BAPTA-AM, 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid; CTAB, cetyltrimethylammonium bromide; HE, hydroethidine; LDH, lactate dehydrogenase; N-c, CTAB-coated NLCs; NLCs, nanostructured lipid carriers; N-s, SME-coated NLCs; P-c, CTAB-coated PLGA nanoparticles; PLGA, poly(lactic-co-glycolic) acid; P-s, SME-coated PLGA nanoparticles; SME, soyaethyl morpholinium ethosulfate.](ijn-10-371Fig6){#f6-ijn-10-371}

![Confocal laser scanning microscopy.\
**Notes:** Cell morphology (**A**) and cellular uptake (**B**) of human neutrophils treated with free rhodamine 800 and N-c and P-c, and examined by confocal laser scanning microscopy.\
**Abbreviations:** CTAB, cetyltrimethylammonium bromide; HBSS, Hank's balanced salt solution; N-c, CTAB-coated nanostructured lipid carriers; P-c, CTAB-coated poly(lactic-co-glycolic) acid nanoparticles.](ijn-10-371Fig7){#f7-ijn-10-371}

![The morphology of human neutrophils examined by scanning electron microscopy.\
**Notes:** Human neutrophils were examined after treatment with (**A**) HBSS (control), (**B**) N-c, and (**C**) P-c.\
**Abbreviations:** CTAB, cetyltrimethylammonium bromide; HBSS, Hank's balanced salt solution; N-c, CTAB-coated nanostructured lipid carriers; P-c, CTAB-coated poly(lactic-co-glycolic) acid nanoparticles.](ijn-10-371Fig8){#f8-ijn-10-371}

![Chemical structures of (**A**) cetyltrimethylammonium bromide and (**B**) soyaethyl morpholinium ethosulfate.](ijn-10-371Fig9){#f9-ijn-10-371}

###### 

The characterization of the lipid nanoparticles and polymeric nanoparticles by particle size, PDI, and zeta potential

  Type                      Code   Cationic surfactant   Size (nm)   PDI         Zeta potential (mV)
  ------------------------- ------ --------------------- ----------- ----------- ---------------------
  Lipid nanoparticles       N-b    None                  254.7±6.6   0.33±0.04   −42.9±1.7
  N-c                       CTAB   169.7±7.5             0.18±0.01   52.0±0.8    
  N-s                       SME    259.3±2.1             0.17±0.04   51.5±0.5    
  Polymeric nanoparticles   P-b    None                  102.4±1.7   0.18±0.01   −5.6±0.8
  P-c                       CTAB   245.8±6.2             0.17±0.05   28.9±4.9    
  P-s                       SME    220.0±6.1             0.15±0.04   39.4±3.8    

**Note:** Each value represents the mean ± SEM (n=3).

**Abbreviations:** CTAB, cetyltrimethylammonium bromide; N-b, blank NLCs; N-c, CTAB-coated NLCs; NLCs, nanostructured lipid carriers; N-s, SME-coated NLCs; P-b, blank PLGA nanoparticles; P-c, CTAB-coated PLGA nanoparticles; PDI, polydispersity index; PLGA, poly(lactic-co-glycolic) acid; P-s, SME-coated PLGA nanoparticles; SEM, standard error of the mean; SME, soyaethyl morpholinium ethosulfate.
